Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(22%)
Results Posted
0%(0 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_1
8
89%
Ph phase_2
1
11%

Phase Distribution

8

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
8(88.9%)
Phase 2Efficacy & side effects
1(11.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(4)
Terminated(3)

Detailed Status

Completed4
Terminated2
Withdrawn1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (88.9%)
Phase 21 (11.1%)

Trials by Status

completed444%
withdrawn111%
terminated222%
recruiting111%
active_not_recruiting111%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_2

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

NCT04116541
active_not_recruitingphase_1

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

NCT05180695
terminatedphase_1

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

NCT03940352
completedphase_1

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

NCT03714958
completedphase_1

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

NCT02890069
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04116541Phase 2

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Recruiting
NCT05180695Phase 1

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

Active Not Recruiting
NCT03940352Phase 1

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Terminated
NCT03714958Phase 1

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

Completed
NCT02890069Phase 1

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Completed
NCT04496999Phase 1

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

Terminated
NCT02143635Phase 1

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Completed
NCT02343172Phase 1

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Completed
NCT03760445Phase 1

HDM201 Added to CT in R/R or Newly Diagnosed AML

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9